Rani Therapeutics Holdings, Inc. (RANI)
0.8595
+0.02
(+2.32%)
USD |
NASDAQ |
Aug 31, 14:10
Rani Therapeutics Holdings Gross Profit Margin (Quarterly) : 88.29% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 88.29% |
| March 31, 2026 | 90.57% |
| December 31, 2025 | 87.27% |
| September 30, 2025 | |
| June 30, 2025 | |
| March 31, 2025 | -45.93% |
| December 31, 2024 | 74.12% |
| September 30, 2024 | |
| June 30, 2024 | |
| March 31, 2024 | |
| December 31, 2023 | |
| September 30, 2023 | |
| June 30, 2023 |
| Date | Value |
|---|---|
| March 31, 2023 | |
| December 31, 2022 | |
| September 30, 2022 | |
| June 30, 2022 | |
| March 31, 2022 | |
| December 31, 2021 | |
| September 30, 2021 | |
| June 30, 2021 | 93.47% |
| March 31, 2021 | 0.00% |
| September 30, 2020 | 0.00% |
| June 30, 2020 | 0.00% |
| March 31, 2020 | 0.00% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Cocrystal Pharma, Inc. | 88.57% |
| CNBX Pharmaceuticals, Inc. | -- |
| GB Sciences, Inc. | -- |
| Arvinas, Inc. | 95.92% |
| Fulcrum Therapeutics, Inc. | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -160.8% |
| Return on Assets | -84.24% |
| Return on Invested Capital | -107.9% |
| Profit Margin (Quarterly) | -493.0% |
| Operating Margin (Quarterly) | -516.9% |
| Return on Net Operating Assets | -552.2% |